Literature DB >> 22310725

Drug development: longer-lived proteins.

Stephan Kontos1, Jeffrey A Hubbell.   

Abstract

Protein therapeutics represent a powerful class of clinically approved drugs for the prevention and treatment of various diseases. Once administered, the biological fate of protein therapeutics is governed by the body's various complex biochemical and biophysical clearance mechanisms, several of which may decrease the drug's circulation time and efficiency. In this tutorial review, we introduce the concepts of physiological protein clearance from the body, and describe several chemical modification and protein engineering approaches used to improve the life span of administered protein therapeutics.

Mesh：

Year:  2012        PMID： 22310725     DOI： 10.1039/c2cs15289d

Source DB:  PubMed          Journal:  Chem Soc Rev        ISSN： 0306-0012            Impact factor:   54.564


  12 in total

Review 1.  Materials and methods for delivery of biological drugs.

Authors:  Alexander N Zelikin; Carsten Ehrhardt; Anne Marie Healy
Journal:  Nat Chem       Date:  2016-10-21       Impact factor: 24.427

2.  Thiol-ene click hydrogels for therapeutic delivery.

Authors:  Prathamesh M Kharkar; Matthew S Rehmann; Kelsi M Skeens; Emanual Maverakis; April M Kloxin
Journal:  ACS Biomater Sci Eng       Date:  2016-01-11

3.  Structure-based redesign of proteins for minimal T-cell epitope content.

Authors:  Yoonjoo Choi; Karl E Griswold; Chris Bailey-Kellogg
Journal:  J Comput Chem       Date:  2013-01-08       Impact factor: 3.376

4.  Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo.

Authors:  Sung In Lim; Young S Hahn; Inchan Kwon
Journal:  J Control Release       Date:  2015-04-07       Impact factor: 9.776

5.  An iTEP-salinomycin nanoparticle that specifically and effectively inhibits metastases of 4T1 orthotopic breast tumors.

Authors:  Peng Zhao; Guiquan Xia; Shuyun Dong; Zhaong-Xing Jiang; Mingnan Chen
Journal:  Biomaterials       Date:  2016-03-22       Impact factor: 12.479

6.  Immune-tolerant elastin-like polypeptides (iTEPs) and their application as CTL vaccine carriers.

Authors:  S Cho; S Dong; K N Parent; M Chen
Journal:  J Drug Target       Date:  2015-08-25       Impact factor: 5.121

7.  Site-specific fatty acid-conjugation to prolong protein half-life in vivo.

Authors:  Sung In Lim; Yukina Mizuta; Akinori Takasu; Young S Hahn; Yong Hwan Kim; Inchan Kwon
Journal:  J Control Release       Date:  2013-06-02       Impact factor: 9.776

8.  PEGylation but Not Fc-Fusion Improves in Vivo Residence Time of a Thermostable Mutant of Bacterial Cocaine Esterase.

Authors:  Haifeng Huang; Lei Fang; Liu Xue; Ting Zhang; Kyungbo Kim; Shurong Hou; Fang Zheng; Chang-Guo Zhan
Journal:  Bioconjug Chem       Date:  2019-11-25       Impact factor: 4.774

9.  A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties.

Authors:  Felix Unverdorben; Meike Hutt; Oliver Seifert; Roland E Kontermann
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

10.  iTEP nanoparticle-delivered salinomycin displays an enhanced toxicity to cancer stem cells in orthotopic breast tumors.

Authors:  Peng Zhao; Shuyun Dong; Jayanta Bhattacharyya; Mingnan Chen
Journal:  Mol Pharm       Date:  2014-07-01       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.